XML 32 R1.htm IDEA: XBRL DOCUMENT v3.25.0.1
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2024
Feb. 28, 2025
Document and Entity Information [Abstract]    
Document Type 10-K  
Document Period End Date Dec. 31, 2024  
Document Annual Report true  
Document Transition Report false  
Entity File Number 001-42270  
Entity Registrant Name Zenas BioPharma, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 93-2749244  
Entity Address, Address Line One 852 Winter Street  
Entity Address, Adress Line Two Suite 250  
Entity Address, City or Town Waltham  
Entity Address State Or Province MA  
Entity Address, Postal Zip Code 02451  
City Area Code 857  
Local Phone Number 271-2954  
Entity Well-known Seasoned Issuer No  
Entity Voluntary Filers No  
Entity Current Reporting Status No  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Title of 12(b) Security Common stock, par value $0.0001 per share  
Trading Symbol ZBIO  
Security Exchange Name NASDAQ  
Entity Public Float $ 0  
Entity Common Stock, Shares Outstanding   41,799,336
Entity Central Index Key 0001953926  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus FY  
Amendment Flag false  
Document Financial Statement Error Correction [Flag] false  
Documents Incorporated by Reference [Text Block]

Portions of the Registrant’s definitive proxy statement relating to the 2025 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission within 120 days after the end of the Registrant’s fiscal year ended December 31, 2024, are incorporated by reference into Part III of this Annual Report on Form 10-K.

 
Auditor Name Ernst & Young LLP  
Auditor Location Boston, Massachusetts  
Auditor Firm ID 42